Abstract
Objective
Study Design and Setting
Results
Conclusion
Keywords
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Journal of Clinical EpidemiologyReferences
- The importance of beta, the type II error and sample size in the design and interpretation of the randomized control trial. Survey of 71 “negative” trials.N Engl J Med. 1978; 299: 690-694
- Type II (beta) errors in the hand literature: the importance of power.J Hand Surg [Am]. 1998; 23: 20-25
- Type II error in the spine surgical literature.Spine. 2004; 29: 1146-1149
- The beta error and sample size determination in clinical trials in emergency medicine.Ann Emerg Med. 1987; 16: 183-187
- Beta, or type II error in psychiatric controlled clinical trials.J Psychiatr Res. 1985; 19: 563-567
- The other side of statistical significance: a review of type II errors in the Australian medical literature.Aust N Z J Med. 1982; 12: 7-9
- Low power, type II errors, and other statistical problems in recent cardiovascular research.Am J Physiol. 1997; 273: H487-493
- Negative results of randomized clinical trials published in the surgical literature: equivalency or error?.Arch Surg. 2001; 136: 796-800
- Empowering research: statistical power in general practice research.Fam Pract. 1997; 14: 324-329
- Sample size and statistical power in clinical orthopaedic research.J Bone Joint Surg Am. 1999; 81: 1454-1460
- Type-II error rates (beta errors) of randomized trials in orthopaedic trauma.J Bone Joint Surg Am. 2001; 83: 1650-1655
- The problem of the type II statistical error.Obstet Gynecol. 1995; 86: 857-859
- Statistical power, sample size, and their reporting in randomized controlled trials.JAMA. 1994; 272: 122-124
- Hypothesis testing in neurosurgical trials.J Neurosurg. 1981; 54: 468-472
- Inadequate size of “negative” clinical trials in dermatology.Br J Dermatol. 1993; 128: 317-326
- Safety of medicines: a guide to detecting and reporting adverse drug reactions.World Health Organization, Geneva2002
- Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC Study: a randomized trial.JAMA. 2006; 295: 165-171
- Comparison of fixed-dose weight-adjusted unfractionated heparin and low-molecular-weight heparin for acute treatment of venous thromboembolism.JAMA. 2006; 296: 935-942
- Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial.Ann Intern Med. 2006; 144: 865-876
- Intraperitoneal cisplatin and paclitaxel in ovarian cancer.N Engl J Med. 2006; 354: 34-43
- Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome.N Engl J Med. 2007; 356: 551-566
- Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial.Lancet. 2006; 367: 825-831
- Estimating live birth rates after ovulation induction in polycystic ovary syndrome: sample size calculations for the pregnancy in polycystic ovary syndrome trial.Contemp Clin Trials. 2005; 26: 271-280
- Categorical data analysis.John Wiley and Sons, Inc., New York, NY2002
- The Wilcoxon, Spearman, Fisher, #2-, student and Pearson tests and 2x2 tables.Statistician. 1995; 44: 441-450
National Cancer Institute. Common toxicity criteria v.2. NCI; 1999 [updated 1999. Available at: http://ctep.cancer.gov/forms/CTCv20_4-30-992.pdf. [Accessed 2008 February 20]. April 30, 1999;
Christensen R, Kristensen PK, Bartels EM, Bliddal H, Astrup A. Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet; 370(): 1706–1713.
- Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials.JAMA. 2006; 295: 2275-2285
- Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.N Engl J Med. 2007; 356: 2457-2471
- Advances in risk-benefit evaluation using probabilistic simulation methods: an application to the prophylaxis of deep vein thrombosis.J Clin Epidemiol. 2004; 57: 795-803
- Sifting the evidence{–}what's wrong with significance tests? Another comment on the role of statistical methods.BMJ. 2001; 322: 226-231
- Reporting of adverse drug reactions in randomised controlled trials—a systematic survey.BMC Clin Pharmacol. 2001; 1: 3